The drug will be introduced with priority for populations in situations of increased vulnerability, although the eligibility criteria are still being defined by health authorities.
Starting in 2026, a new HIV prevention treatment will be introduced into the National Health System (SNS). This measure represents a reconfiguration of the national response to the virus, with the introduction of the drug lenacapavir, recently approved for prophylactic use in high-prevalence settings.
According to the Ministry of Health, the initial phase of implementation foresees the provision of between 80,000 and 90,000 doses, which will be administered biannually to approximately 30,000 people. The drug will be introduced with priority for populations in situations of increased vulnerability, although eligibility criteria are still being defined by health authorities.
Lenacapavir acts as a long-acting prophylaxis and will be administered via subcutaneous injection at six-month intervals. Its adoption aims to address the challenge of irregular adherence to traditional prevention methods, such as daily pre-exposure prophylaxis (PrEP) tablets. International studies indicate that the drug is highly effective in preventing HIV infection, especially in contexts with barriers to healthcare access and logistical difficulties.
The country currently has approximately two and a half million people on antiretroviral treatment, according to data from the Ministry of Health. This figure represents one of the highest HIV burdens in Southern Africa and maintains the epidemic as a top public health priority in the country.
The introduction of lenacapavir will be accompanied by a monitoring and evaluation plan, including the recording of clinical effects, adherence, coverage, and impact on the rate of new infections. Health authorities believe that the success of its implementation will also depend on integration with community strategies, information campaigns, and ongoing training for health professionals.
The introduction of lenacapavir into the public system thus constitutes a test of the country's ability to absorb innovative medical technologies and translate them into equitable access and measurable impact.
Mozambique remains committed to international goals for reducing HIV incidence, in line with the 2030 global targets. The inclusion of new prevention methods represents a technical and political step that will require rigorous monitoring, institutional coordination, and continued investment in public health.
(By Rafael Langa)
